We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Cell and Tissue Acquisition Device Improves Efficiency at More Affordable Price

By LabMedica International staff writers
Posted on 26 Feb 2013
An innovative and affordable new cell and tissue acquisition instrument improves efficiency and ease-of-use compared to existing laser-assisted microdissection systems.

Kuiqpick, introduced by NeuroInDx, Inc. More...
(Los Angeles, CA, USA), is the innovative new laser-assisted microdissection and acquisition system for research laboratories. It includes the additional the capacity to collect cells from tissues and cultures without affecting their viability, enabling the collected cells to then be cultured for further analysis and downstream applications. Also notable, Kuiqpick costs less than USD 30,000 per device, about one-fourth the cost of existing systems. “Kuiqpick [opens] the door for more labs to conduct the critical collection of live cells and tissue areas for examination and culturing,” said Stan Karsten, PhD, NeuroInDx chief scientific officer and cofounder; “For too long, the high cost of tissue microdissection and cell sorting technologies have limited cell-specific research. With the introduction of Kuiqpick, more labs and researchers can afford the technology.”

Rebecca Stockton, PhD, a University of California, Los Angeles (UCLA) assistant professor of pediatrics, uses Kuiqpick to study cerebral cavernous malformations and said, “[Kuiqpick is] perfect for collecting small abnormal blood vessels from the brain tissue and specific cells from cultures based on their form and structure, or their morphology, which is critical for my research.”

Originally conceived at UCLA and further developed by NeuroInDx, Kuiqpick can be attached to an inverted microscope to dissect brain tissue slices at the cellular resolution and collect individual cells from various cell cultures. A single press of a button initiates the collection of the brain tissue area or cells into a disposable capillary unit. Collected tissue samples are then transferred to a test tube for further use. “Kuiqpick is a novel and highly accurate system that has already proven to be extremely efficient in the isolation of specific cell populations from live and freshly frozen brain tissues,” said Dr. Lili C. Kudo, president and CEO of NeuroInDx; “It can be successfully used in a variety of molecular studies, including stem cell research, genomics and proteomics.”

NeuroInDx also offers to provide researchers with custom cell and tissue collection services and subsequent gene expression-microarray experiments, thus saving time and funding for their projects.

Related Links:

NeuroInDx





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Immunoassay Analyzer
Procise DX
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.